Drugs / BGT007H
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06152757 | Oct 2023 → Jul 2025 overdue | digestive system neoplasm | BioSyngen Pte Ltd | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06478225 | May 2024 → Mar 2027 expected | malignant pancreatic neoplasm | RenJi Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BGT007H | “Clinical Study on the Safety and Preliminary Efficacy of BGT007H Cell Therapy in Patients With Recurrent/Refractory Gastrointestinal Tumors” NCT06152757 ↗ |
| Modality | Cell therapy | “BGT007H cell therapy” NCT06152757 ↗ |